Screening for prostate cancer in Dutch hereditary prostate cancer families

International Journal of Cancer

Volumn 122, Issue 4, 2008, Pages 871-876

  Kiemeney, Lambertus A ^a,b   Broeders, Mireille J ^a   Pelger, Marjon ^c   Kil, Paul J ^d   Schröder, Fritz H ^e   Witjes, Johannes A ^a   Vasen, Hans F ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Integraal Kankercentrum Oost   (Netherlands)

^c Foundation for the Detection of Hereditary Tumours   (Netherlands)

^d Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Heredity; Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SCREENING; FAMILIAL CANCER; GLEASON SCORE; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; BLOOD; COMPARATIVE STUDY; FAMILY; FEMALE; GENETICS; MASS SCREENING; METABOLISM; MIDDLE AGED; PATHOLOGY; PEDIGREE; PROSTATE; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY;

AGED; FAMILY; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PEDIGREE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 38349038167     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23165     Document Type: Article

References (26)

1. Vereniging van Integrale Kankercentra. Netherlands Cancer Registry. www.ikcnet.nl. 2006.
2. Van Oers JAM. Health on course? The 2002 Dutch public health status and forecast report (Report no. 270551001). Bilthoven, The Netherlands: National Institute for Public Health and the Environment, 2002.
3. de Koning HJ, Auvinen A, Berenguer-Sanchez A, Calais da Silva F, Ciatto S, Denis L, Gohagan JK, Hakama M, Hugosson J, Kranse R, Nelen V, Prorok P, et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer Trial and the Prostate, Lung, Colorectal and Ovary Cancer Trial. Int J Cancer 2002;97:237-44.
4. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992;89:3367-71.
5. Grönberg H. Prostate cancer epidemiology. Lancet 2003;361:859-64.
6. Langeberg WJ, Isaacs WB, Stanford JL. Genetic etiology of hereditary prostate cancer. Front Biosci 2007;12:4101-10.
7. Meulenbeld HJ, Verhage BA, Kil PJ, Kiemeney LA, Vasen HF. [Characterisation of families with hereditary prostate cancer in the Netherlands]. Ned Tijdschr Geneeskd 2002;146:1938-42.
8. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993;150:797-802.
9. Health Council of the Netherlands. Committee on the Population Screening Act. Population screening act: hereditary prostate cancer (Report no. 2001/01). The Hague: Health Council of the Netherlands, 2001.
10. Roobol MJ, Schröder FH, Kranse R. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (Results of ERSPC, Rotterdam). Prostate 2006;66:604-12.
11. Postma R, van Leenders AG, Roobol MJ, Schröder FH, van der Kwast TH. Tumour features in the control and screening arm of a randomized trial of prostate cancer. Eur Urol 2006;50:70-5.
12. Roemeling S, Roobol MJ, de Vries SH, Gosselaar C, van der Kwast TH, Schröder FH. Prevalence, treatment modalities and prognosis of familial cancer in a screened population. J Urol 2006;175:1332-6.
13. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997;157:199-202.
14. Bratt O. What should a urologist know about hereditary predisposition to prostate cancer? BJU Int 2007;99:743-7.
15. Matikainen MP, Schleutker J, Mörsky P, Kallioniemi O-P, Tammela TLJ. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families. Clin Cancer Res 1999;5:1275-9.
16. Mäkinen T, Tammela TLJ, Stenman U-H, Määttänen L, Rannikko S, Aro J, Juusela H, Hakama M, Auvinen A. Family history and prostate cancer screening with prostate-specific antigen. J Clin Oncol 2002;20:2658-63.
17. Catalona WJ, Antenor JAV, Roehl KA. Screening for prostate cancer in high risk populations. J Urol 2002;168:1980-4.
18. Valéri A, Cormier L, Moineau M-P, Cancel-Tassin G, Azzouzi R, Doucel L, Baschet F, Cussenot I, L'Her J, Berthon P, Mangin P, Cussenot O, et al. Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. J Urol 2002;168:483-7.
19. Bratt O, Damber JE, Emanuelsson M, Kristoffersson U, Lundgren R, Olsson H, Grönberg H. Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer. Eur J Cancer 2000;36:235-41.
20. Shah M, Zhu K, Palmer RC, Wu H. Family history of cancer and utilization of prostate, colorectal and skin cancer screening tests in U.S. men. Prev Med 2007;44:459-64.
21. Jacobsen PB, Lamonde LA, Honour M, Kash K, Hudson PB, Pow-Sang J. Relation of family history of prostate cancer to perceived vulnerability and screening behavior. Psychooncology 2004;13:80-5.
22. Hemminki K, Rawal R, Bermejo JL. Prostate cancer screening, changing age-specific incidence trends and implications on familial risk. Int J Cancer 2005;113:312-15.
23. Bratt O, Damber JE, Emanuelsson M, Grönberg H. Hereditary prostate cancer: clinical characteristics and survival. J Urol 2002;167:2423-6.
24. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, Jonasson JG, Olafsdottir EJ, Olafsdottir GH, Rafnar T, Thorlacius S, Jonsson E, Eyfjord JE, Tulinius H. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:929-35.
25. Gosselaar C, Roobol MJ, Schroder FH. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU Int 2005;95:231-7.
26. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schroder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007;177:107-12.